ai3Bio · Series A
Intern, Drug Product Development, CMC
Watertown, Massachusetts
Posted 17 days ago· Nov 4

Biotechnology, Health Care, Life Science, Medical, Therapeutics
ai3Bio raised $48M in a Series A announced on Sep 29, 2026, led by Ziff Capital Partners, UPMC Enterprises, Tanis ventures, Cockrell Interests. Since then it has posted 2 roles (1 still open), the first 7 days after it. With 1 open roles it is hiring more than 0% of the 226 Series A startups on JustBacked (median: 9). In total it has raised $103M over 2 rounds from 1 investors.
From ai3Bio's own hiring system, by posting date. Tracked since Oct 6, 2026; roles that closed before then aren't counted.
ai3Bio develops treatments to transform the lives of patients with cancer.
This could be huge if one treatment that removes disease-causing T cells becomes the autoimmune standard, replacing drugs that suppress the whole immune system. ai3Bio, a Pittsburgh biotech, has two platforms aimed at the same pathogenic T cells, one an mRNA nanoparticle and one a targeting antibody. Its $48M Series A in late September, led by Ziff Capital Partners and UPMC Enterprises, lifts the total to $103M across two rounds.
JustBacked's take, based on ai3Bio's own site and its funding and hiring data.
Hiring velocity
ai3Bio · Series A
Watertown, Massachusetts
Posted 17 days ago· Nov 4
Source: cornertx.bamboohr.com, checked daily.